Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (1867)	8/24/2007 9:42:30 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ARNA starting with a small UG with no news that I am aware.Will see if it will be able to handle the initial resistance at the $13 level. bigcharts.marketwatch.com Bernard

To: Steve Lokness who wrote (1867)	9/11/2007 9:34:02 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

IMCL is up more than 25% in pre-market after Merck KGaA said that the findings from the FLEX,a large PIII in which Erbitux was given to patients with advanced NSCLC alongside platinum-based chemotherapy, showed positive evidence of improved survival,in contrast with the negative findings from a smaller trial in July. bigcharts.marketwatch.com Erbitux's promise in lung cancer could be bad news for Roche and DNA's competing drug Avastin, which works in a different way.Some "analysts" like Dresdner Kleinwort, said they were not changing their forecasts for Avastin but there was an increased risk of future downgrades.<g> bigcharts.marketwatch.com Merk KGA stock was up 5% in Europe & BMY which markets Erbitux for IMCL in the US was up around 2%. bigcharts.marketwatch.com RGEN will apparently not participate on those results, since the claims it had with MIT against IMCL & BMY were settled for some 65M instead of going to trial.<g> bigcharts.marketwatch.com money.cnn.com Bernard